Background We have recently reported that chemotherapeutic agents in ultra low noncytotoxic concentrations may block the ability of tumor cells to suppress functional activation of dendritic cells (DCs). Methods HCT-116 human colon cancer cells were treated with 0.5 nM paclitaxel (PAC) or 2 nM doxorubicin (DOX) with the aim of defining the immunogenic changes induced by ultra low noncytotoxic concentrations of antineoplastic chemotherapeutic agents. Genetic alterations were screened by DNA microarray that revealed increased expression of genes involved in antigen processing and presentation, including the heat-shock protein, calmodulin, and proteasome 26 genes. As the proteins encoded by these genes are involved in the cytosolic route of antigen processing machinery, we next evaluated whether PAC and DOX in noncytotoxic concentrations changed expression of MHC class I antigen processing machinery (APM) components in three different colon cancer cell lines.
Introduction
Immunotherapy combined with certain types of conventional or moderately low-dose chemotherapy has been shown to enhance antitumor responses. Increasing data support the contention that some cytotoxic drugs and combination regimens are not detrimental to the antitumor immune response, despite the common neutropenia and lymphopenia exhibited in patients who receive those treatments. Cyclophosphamide (a DNA alkylating agent), gemcitabine (a synthetic pyrimidine nucleoside analogue), the anthracycline Adriamycin (doxorubicin), antimicrotubular taxanes (paclitaxel and docetaxel), 5-FU (fluorouracil; a fluoropyrimidine) and other chemotherapeutics have been reported to augment the antitumor immune responses induced by various cancer vaccines, monoclonal antibodies, cytokines, TLR ligands, and co-stimulatory molecules in animal tumor models and several human clinical trials [1] [2] [3] . Although definite in-vivo mechanisms of immunopotentiating effects of certain cytotoxic drugs in the tumor microenvironment have not yet been determined, two major pathways are likely to play prominent roles in these effects.
First, many chemotherapeutic agents may directly affect immune cells. For instance, cyclophosphamide has been shown to decrease the percentage of regulatory T cells among the CD4+ lymphocytes. This, in turn, allowed a whole tumor cell vaccine or co-stimulatory receptor OX40 (OX86) immunotherapy to eradicate established tumors in colon carcinoma or melanoma models [4, 5] . Gemcitabine was able to reduce the number of myeloid-derived suppressor cells (MDSCs) found in the spleen of mice bearing large tumors, but did not affect CD4 and CD8 T cells, NK cells, macrophage and B cells [6] [7] [8] . Paclitaxel, doxorubicin, mitomycin C, and methotrexate in ultra low noncytotoxic concentrations directly up-regulate maturation, antigen processing and presentation, as well as IL-12 production by dendritic cells (DCs) [9, 10] , which may play a key role in the synergistic antitumor effects of low-dose chemotherapy combined with DC vaccines [11] .
The second general mechanism of the enhanced efficacy of cancer immunotherapy with low-dose chemotherapy is the destruction of tumor cells in a manner that provides 'danger signals' and tumor antigens from dying tumor cells to promote the engagement of innate and adaptive immunity. Anthracyclines such as doxorubicin in micromolar (μM) concentrations have been reported to induce immunogenic cell death in treated tumor cell lines, an effect not noticed with other DNA-damaging agents such as etoposide and mitomycin C [12, 13] . Anthracyclines induced the rapid co-translocation of ERp57 and calreticulin to the surface of dying tumor cells and thus mediated the phagocytosis of the anthracycline-treated tumor cells by DCs. Tumor cell death triggered by chemotherapy may also initiate an immunoadjuvant pathway that relies on the interaction of the highmobility-group box 1 (HMGB1) alarmin protein released from dying tumor cells with TLR4 on DCs [14] . This pathway is required for the cross-presentation of tumor antigens and promotion of tumor-specific cytotoxic T cell responses [15] . Additionally, many chemotherapeutic agents induce production of uric acid caused by tumor cell death. Uric acid may activate DCs and thus promote tumor rejection [16] .
Thus, the efficacy of successful combinations of conventional and moderate-dose chemotherapy and immunotherapy is in part due to the lymphodepletion, accessibility of antigens, expression of calreticulin, and release of alarmin and uric acid from dying tumor cells; i.e., this success relies on the cytotoxic effect of chemotherapy on tumor or immune regulatory cells. We have recently reported a new mechanism of immune-potentiating activity of chemotherapeutic drugs by demonstrating that a number of chemotherapeutic agents in ultra low noncytotoxic nanomolar (nM) concentrations can directly alter the function of DCs and tumor cells without inducing apoptosis [9, 11, 17] . However, it is unknown whether cytotoxic agents in noncytotoxic concentrations directly change antigen-processing in tumor cells and affect tumor cell interaction with antigen-presenting cells without inducing apoptosis of tumor cells. Here we demonstrated that the treatment of tumor cells with ultra low noncytotoxic concentrations of antineoplastic drugs did not induce cell death, but instead changed the immunogenicity of tumor cells by increasing expression of genes and proteins associated with antigen processing. Importantly, DCs loaded with pretreated tumor cells induced higher cytotoxic T cell activity than DCs loaded with untreated tumor cells. Tumor-specific CTLs displayed significantly higher level of cytotoxicity against live pretreated tumor cells than against control non-treated tumor targets. Thus, these data demonstrate that treatment of tumor cells with ultra low noncytotoxic concentrations of chemotherapeutic agents, a method also known as chemomodulation [9] , can be used for improved ex vivo preparations of tumor cell-based and DC-based vaccines. Our results also suggest a new mechanism of how a very low dose of chemotherapeutic agents alters the tumor microenvironment and supports the generation of effective antitumor immune responses.
Materials and methods

Tumor cell lines and cultures
Human colon cancer cell lines HCT-116, HCT-WT and HT-29 (all from ATCC) were cultured in RPMI-1640 medium supplemented with 10% FBS, 2 mM L-glutamine, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids, 10 mM HEPES and 0.1 mg/ml gentamicin at 37°C under 5% CO 2 tension. Cell lines were treated with 0.5 nM paclitaxel (F.H. Faulding & Co. Ltd., Mulgrave, Australia) or 2 nM doxorubicin hydrochloride (Calbiochem) for 48 h, washed twice and used for different assays. Noncytotoxic concentrations of PAC and DOX were determined previously in an MTT-based cytotoxic assay [10, 17] .
For the preparation of tumor cell lysates, untreated control HCT-116 cells or cells pre-treated with PAC (0.5 nM) or DOX (2 nM) for 48 h were submitted to 5 cycles of quick freeze and thaw. The lysates were then submitted to ultrasound at 0.07 watts RMS, 22 KHz for 30 min (60 Sonic Demembranater, Fischer) followed by centrifugation for 15 min at 10,000× g. Supernatants containing soluble antigens were frozen and kept at −80°C.
Gene expression analysis
Total RNA was extracted from 10 6 HCT-116 cells treated with medium (control), PAC or DOX, and purified with RNeasy kit (QIAGEN). Five micrograms of total RNA were used in the first strand cDNA synthesis by Superscript II (Invitrogen) primed with T7 promoter-tagged (dT)-24 primer (GGCCAGTGAATTGTAATACGACTCACTA TAGGGAGGCGG-(dT)24). The second strand cDNA synthesis was carried out at 16°C for two hours by nicking RNA away of DNA/RNA -double-stranded template with RNAse H, synthesizing second strand DNA by E. coli DNA polymerase I along the DNA template, and ligating the newly synthesized DNAs with DNA ligase. T4 DNA polymerase was added to the reaction for an additional 5 min incubation to blunt the ends of synthesized cDNA. The double-stranded cDNA was further purified through phenol/chloroform and ethanol precipitation, and used as the template in the in vitro transcription to obtain biotinlabeled cRNA by using MEGAscript system (Ambion Inc).
Affymetrix chip hybridization Fifteen μg of cRNA were fragmented in the fragmentation buffer containing 200 mM Tris-acetate (pH 8.1), 500 mM potassium acetate, and 150 mM magnesium acetate at 95°C for 35 min. The fragmented cRNA was then hybridized to Affymetrix Hu133 plus 2.0 chip at 45°C for 16 h. The wash and staining processes to remove unbound and nonspecifically bound targets and to stain the targets were carried out according to the manufacturer's procedure.On a fluidic station, the chips hybridized with targets were washed with low-stringency buffer (6x SSPE, 0.01% Tween 20, 0.005% antifoam), stringent buffer (100 mM MES, 0.1 M NaCl and 0.01% Tween 20), then stained with streptavidin phycoerythrin (SAPE, Molecular Probe). This was followed by incubation with the biotinylated mouse anti-avidin antibody, and then with SAPE. The chips were then scanned in an Affymetrix Genechip scanner 3000 (Affymetrix Inc). Signal intensities were normalized to the average target of 500 and the fold differences of intensity were obtained by the comparison of samples from cells treated with drugs and control cells. Search for relevant differences was done by Cluster 3.0 and clustered genes were visualized by TreeView 1.60 software (Eisen Labs).
Flow cytometry analysis of MHC class I antigen-processing machinery (APM) components
Analysis of MHC class I APM proteins was done by intracellular staining as previously described [18] using monoclonal antibodies (mAb) to individual APM components. The anti-calnexin mAb TO-5, anti-calreticulin mAb TO-11, anti-ERp57 mAb TO-2, anti-tapasin mAb TO-3, anti-MB1 mAb SJJ-3, anti-low molecular weight protein (LMP) 2 mAb SY-1, anti-LMP7 mAb SY-3, and anti-LMP10 mAb TO-7 were developed and characterized earlier [19] and provided by Dr. Soldano Ferrone (University of Pittsburgh Cancer Institute, Pittsburgh, PA). Drug-treated and untreated tumor cells were detached from culture flasks with 0.05% trypsin, washed and resuspended in PBS containing 1% bovine serum albumin (1% PBS-BSA). Cells were fixed with 2% paraformaldehyde (PFA, Sigma) for 20 min, washed and resuspended in 0.5% PBS-BSA. Cell suspensions were microwaved until the boiling point (~20 sec) and immediately chilled on ice. After washing, cells were permeabilized with 1% PBS-BSA containing 0.1% saponin (Sigma) for 30 min. Then, cells were incubated with primary antibodies for 30 min at room temperature. After washing, secondary anti-mouse IgG-FITC antibody (DAKO, 1:100) was added for 30 min. 
Human monocyte-derived dendritic cells
Human DCs were generated from peripheral blood mononuclear cells (PBMCs) of healthy donors. After gradient separation and lysis of RBCs, PBMCs were suspended in AIM-V culture medium (Invitrogen) and seeded in 6-well plates (10 7 cells/well). After 50 min at 37°C, non-adherent cells were removed and adherent monocytes were cultured in complete RPMI-1640 medium with 1000 U/ml recombinant human GM-CSF and 1000 U/ml IL-4 (PeproTech). Immature DCs were pulsed with tumor cell lysates (tumor:DC ratio=5:1) on day 5 for 24 h and DC maturation was induced by TNF-α (1,000 U/ml) and LPS (1 μg/ml) for 4 h. DCs were then collected and used for cytotoxic T lymphocyte generation.
Generation of cytolytic T lymphocytes
For CTL preparation, nylon wool-enriched T lymphocytes prepared from PBMCs were co-cultured with autologous tumor antigen-pulsed DCs. IL-7 (10 ng/ml) and IL-2 (10 IU/ml) were added to the cultures. The cultures were pulsed with IL-2 every 3 days and antigen-loaded DCs were replaced weekly. T cells were collected two weeks later and the specific cytolytic activity against drug-treated and untreated tumor cells was evaluated.
Cytolytic activity of tumor-specific T lymphocytes was determined by MTT assay as previously reported [20] with modifications. Tumor cell suspensions (100 μl, 2×10 5 /ml) was seeded in a 96-well flat bottom culture plate and incubated for 2 h for cell adherence. Effector cells (100 μl) were then added to triplicate wells at 20:1, 10:1, 5:1 and 2.5:1 effector-to-target ratios. Spontaneous and maximum cell death controls were prepared with each target cell suspensions incubated with culture medium or 10 μl of lysing buffer, respectively. After incubation for 4 h at 37°C, all wells were rinsed 3 times with complete medium and 100 μl of MTT (1 mg/ml, Sigma) was added to each well for 3 h. Then, supernatants were disposed and 100 μl of DMSO was added. Optical density (OD) was determined on a plate reader (Wallac) at 540 nm. The percentage of specific lysis was calculated by the following equation: [1 -(OD of experimental group -OD of spontaneous death control)/(OD of maximum death control -OD of spontaneous control)] x 100.
Statistical analysis
Selection of relevant changes of mRNA expression was based on the signal intensities of Affimetrix Chip Analysis, normalized to the average target of 500 and the fold differences of intensity obtained by the comparison of samples from cells treated with drugs and the control cells. Differences of expression of APM components were analyzed by Student's t-test comparing each group with untreated controls. The effect of drug-treated tumor cells on the generation of CTLs was analyzed by Kruskall-Wallis one-way ANOVA. The differences were considered significant when error probability was less than 5% (p<0.05). All experiments were repeated at least three times and all statistical analyses were done using SigmaPlot 11.0 software (SSNS).
Results
3.
1 Pre-treatment of human colon cancer cell lines with paclitaxel or doxorubicin significantly altered expression of genes associated with antigen processing Gene expression profile of HCT-116 colon cancer cells was used as an internal control for the assessment of alterations of gene expression induced by tumor cell pre-treatment with low concentrations of chemotherapeutic agents. Using Affymetrix Hu133 Plus 2.0 chip, which covers 54,676 probes, we determined that treatment of tumor cells with PAC and DOX induced relevant alteration of expression of more than 2,500 and 2,100 genes, respectively. Among these genes, genes associated with the cytosolic antigen processing mechanisms, heat shock proteins, and some tumor-associated antigens represented a group of a special interest. As detailed in Tables 1 and 2, in (Table 2 ). Both PAC and DOX increased expression of HSP70 and HSP40. Only PAC increased HSP105, whereas HSP90 was up-regulated by DOX. These results reveal that both PAC and DOX in ultra low noncytotoxic concentrations are able to alter gene expression in human tumor cells without changing their viability. (Fig. 1) . Furthermore, expression of LMP2, LMP7, TAP2, tapasin and β2-microglobulin proteins was also increased in PAC-treated HCT-116 cells assessed as MFI and percentage of positive cells with, e.g., LMP7 increase in up to 2.7-fold and tapasin increase in up to 7-fold (Fig. 1 ). Interestingly, since the level of surface HLA class I expression in untreated HCT-116 cells was high (98.6 ± 3.3%), its further up-regulation by pretreatment with PAC was not particularly noticeable (99.3± 2.9%) (data not shown).
Analysis of APM proteins in different tumor cell lines revealed increased expression of calmodulin, TAP2, and tapasin, but not LMPs, in HCT-WT cells after pre-treatment with PAC. However, just as we had observed with HCT-116 cells, pre-treatment with PAC did not influence the expression of MHC class I molecules on HCT-WT cells. HT-29 cell line also showed increased intracellular levels of LMP2, MB1, and TAP2, although other APM molecules were not significantly altered after pre-treatment with PAC (data not shown). Interestingly, treatment of HT-29 cells with PAC did not significantly change their already low MHC class I expression (from 7.6±3.7% initially to 3.6± 2.8%).
Next, similar studies were carried out with colon carcinoma cell lines pre-treated with DOX. The results demonstrated that the effect of DOX on the expression of MHC class I APM components was markedly lower than the effect of PAC. For instance, DOX up-regulated intracellular expression of MB1 (delta) molecules up to 25% in HCT-116, HT-29, and HCT-WT cells, while the expression of other APM proteins was not significantly altered. Surface expression of MHC class I molecules was also not changed. Importantly, pre-treatment of tumor cells with PAC or DOX did not change the surface expression of calreticulin, which varied from 0.68 to 1.23 MFI, suggesting that this treatment did not activate apoptotic machinery in tested tumor cell lines. These data show that treatment of human colon cancer cell lines with low noncytotoxic concentrations of PAC upregulated intracellular expression of several MHC class I APM components without altering surface expression of HLA class I molecules. The effect of DOX was similar but markedly lower than that of PAC. These results raise an important question about the biological significance of this phenomenon.
PAC increased recognition of tumor cells by tumor-specific CTLs
To test whether pre-treatment of tumor cells with PAC might alter their interaction with immune cells, we next compared the ability of antigen-presenting cells to utilize non-treated or PAC-treated tumor cells as a source of tumor antigens for inducing tumor-specific cytotoxic T cells (CTLs).
Human monocyte-derived DCs were pulsed with tumor lysates prepared from untreated HCT-116 cells or cells pretreated with PAC or DOX and co-cultured with autologous T cells for in vitro CTL generation. Activity of CTLs was tested against untreated HCT-116 cells (Fig. 2a) . Results in Fig. 2c show that although all tumor antigen-loaded DC subsets were able to induce functional CTLs, DCs pulsed with lysates of tumor cells pretreated with PAC (DC-HCT/ PAC) have a significantly higher ability to induce the generation of tumor-specific CTLs. For instance, at E:T ratio=20:1, specific lytic activity of cytotoxic T cells increased from 49.43±3.01% in control group to 77.98± 9.13% in the group where CTLs were induced by DCs loaded with PAC pre-treated tumor cells (p<0.05). The effect of the pre-treatment of tumor cells with DOX was similar, although smaller than that of PAC (data not shown). Thus, these results suggest that pre-treatment of tumor cells with PAC makes them more immunogenic for loading into DCs when DCs are used for the in vitro generation of tumor-specific CTLs.
We then tested whether pre-treatment of tumor cells with noncytotoxic concentrations of chemotherapeutic drugs may alter their recognition by CTLs. For this purpose, HCT-116-specific CTLs were prepared in co-cultures with DCs that were loaded with untreated tumor cell lysates. Cytolytic activity of these CTLs was then tested against control and PAC-or DOX-treated live tumor cells (Fig. 2b) . As shown in Fig. 2d , HCT-116 tumor cells pre-treated with PAC were more sensitive to CTL-induced killing than control tumor cells. For example, specific lysis was increased from 44.12±3.82% targeting control tumor cells to 62.82±8.08% targeting PAC-treated tumor cells (p< 0.05). Again, the effect of DOX on tumor cell targets was similar, although it was significantly smaller than the effect of PAC (data not shown).
Taken together, these results demonstrate that without inducing tumor cell death, PAC and DOX, to a lesser extent, can augment immunogenicity of tumor cells when used in low noncytotoxic concentrations in vitro.
Discussion
One important strategy for improving the effectiveness of immunotherapy relies on its combination with chemotherapy. Results from animal studies and pilot clinical trials suggest that certain chemotherapeutic agents may operate, under defined conditions, as potent up-regulators of antitumor immune responses. It is generally believed that the strong therapeutic effect induced by the combination of chemotherapy with immunotherapy depends on homeostatic mechanisms acting during the recovery phase that follows chemotherapy-mediated myelo-lymphodepletion that, as a bystander effect, promote antitumor immunity [21] . In addition, treatment with certain agents, i.e. anthracyclines, can induce the release of tumor antigens and damage-associated molecular patterns (DAMPs) (i.e., heat shock proteins, calreticulin, HMGB1) that promote uptake of apoptotic tumor cells and tumor antigen crosspresentation by DCs and ultimately CTL activation [15] . These immune-potentiating activities of moderately lowdose chemotherapy therefore rely on the cytotoxic effects of chemotherapeutics on immune cells and/or tumor cells.
However, it is largely unknown whether chemotherapeutic drugs might alter immunogenicity of tumor cells without inducing tumor cell death. We have recently started an extensive characterization of direct immunomodulatory properties of common chemotherapeutic agents when used in very low noncytotoxic concentrations. We demonstrated that paclitaxel, doxorubicin, methotrexate and other drugs in low nanomolar concentrations up-regulate maturation, antigen processing, and antigen presentation by murine and human DCs without altering cell longevity [9, 10] . We have also reported that PAC in nanomolar concentrations blocks tumor cell ability to suppress DC function [11] . Here we show that PAC is also able to increase the immunogenicity of tumor cells, assessed first as the ability of DCs loaded with pretreated tumor cells lysate to induce CTL formation in vitro and, second, as the ability of in vitro-generated CTLs to recognize and kill pretreated tumor cells. Altered immunogenicity of tumor cells was associated with increased expression of proteasome 26 and 28, CALM1, CALM2, and calmodulin mRNA. The proteins encoded by these genes are involved in antigen-processing machinery; for instance, proteasome 26 is a component of the enzyme complex responsible for the selective intracellular protein degradation of poly-ubiquitinated substrates [22] , whereas calmodulin is one of the chaperones participating in MHC complex assembly [23] .
In agreement with the gene expression results, we revealed that tumor cells treated with PAC expressed higher levels of intracellular calmodulin protein and other components of APM, such as LMP2, LMP7, TAP1, and tapasin, when compared with untreated tumor cells. These two betasubunits of immunoproteasome are inducible by interferon-γ (IFN-γ), and by altering the catalytic activity of proteasome, can enhance the presentation of certain antigens [24, 25] . Although decreased expression of LMP2 was not always linked with abnormal antigen presentation, LMP7 expression has been shown to be essential for the processing of certain epitopes recognized by CTLs [26] . Increased expression of transporter associated with antigen processing (TAP), a member of the ATP-binding-cassette transporter family, may result in improved delivery of cytosolic peptides into the endoplasmic reticulum, where they bind to nascent MHC class I molecules [27] . Upregulation of TAP-associated glycoprotein (tapasin) may facilitate optimal peptide loading on the MHC class I molecule [27] . Because we did not observe significant elevation of surface MHC class I molecules on PAC-treated tumor cells, it is likely that alteration of antigen processing by PAC is due to different patterns of produced antigenic peptides and/or diverse loading of these peptides in MHC/ peptide complex, rather than increased transport of MHC/ peptide molecules to the tumor cell surface. Consistent with this hypothesis are our data showing that tumor-specific CTLs were able to discriminate between the untreated and PAC or DOX-treated tumor cells (Fig. 2) .
Signaling pathways utilized by chemotherapeutic agents in very low noncytotoxic concentrations are currently unknown. The only report focusing on this new phenomenon of chemomodulation suggests that several tested chemotherapeutic agents in low nanomolar concentrations, including paclitaxel and doxorubicin, may modulate activity and expression of small Rho GTPases in DCs [17] . the role of small Rho GTPases, including Cdc42 and RhoA, in modulating antigen processing and presentation in DCs has also been reported [28] . Involvement of this pathway in chemomodulation of immunogenicity of tumor cells, as well as analysis of other signal transduction pathways in tumor cells triggered by PAC and DOX are in progress in our laboratory. However, signaling that might regulate APM protein expression seems to be cancer specific. In fact, epigenetic regulation of APM component expression has been reported in melanoma and renal carcinoma cells: DNA demethylating agent 5-aza-2-deoxycytidine and histone deacetylase inhibitors trichostatin A and valproic acid enhanced expression of TAP1, TAP2, LMP2, LMP7, and tapasin in several tumor cells lines [23, 29, 30] . Loss or down-regulation of MHC class I molecules is one of the main mechanisms used by tumor cells to escape immune recognition. Many human tumors, including colorectal cancer, display little or no expression of MHC class I on the cell surface, a phenomenon which is commonly due to the inhibited expression of different APM components [31, 32] . The ability of PAC in ultra low noncytotoxic concentrations to regulate expression of APM proteins in tumor cells and resemble the effect of commonly used IFN-γ [33] through the utilization of different antigen processing pathways represents an interesting and important phenomenon. This opens new opportunities for developing cancer vaccines and reinforces the concept that pharmacological modulation of tumor cells must be considered to achieve improved approaches for active immunotherapy based on DC-vaccines. Our results show that PAC can be used for ex vivo preparation of more potent DC vaccines for utilization in multiple clinical protocols that test different DC-based immunotherapies for cancer treatment. Our findings, which demonstrate that tumor cells pre-treated with ultra low concentrations of PAC are better targets for tumor-specific CTLs, also suggest that administration of certain FDA-approved chemotherapeutic agents in ultra low nontoxic doses in tumor-bearing hosts may beneficially alter tumor cells making them better targets for both antigen-presenting and effector cells. Thus, these results demonstrate that intervention with ultra low noncytotoxic doses of chemotherapeutic drugs, i.e. chemomodulation, targets multiple cell subsets in the tumor microenvironment, including both immune cells and tumor cells, and boosts the development of antitumor immune responses through multiple mechanisms.
